Hemolytic Anemia Trials
Optimizing Clinical Research for Intrinsic and Extrinsic Hemolytic Anemia
Understanding Patient Diversity and Rare Disease Pathology
Hemolytic anemia is defined by diversity – a varied group of patients, with different ethnicities, presenting multiple disease subtypes on a global scale. These differentiators can often stop a clinical trial before it begins, as rare blood disease studies present a limited patient population, a wide variety of symptoms, and specific trial exclusion criteria.
Biorasi, a new kind of CRO, understands the challenges facing hemolytic anemia trials and can offer solutions for recruitment and retention that can keep your studies on track.
Biorasi is Your Guide to Successful Hematology Trials
Our customized recruitment solutions are a perfect complement to hemolytic anemia trial protocols:
- Biorasi is able to recruit patient subjects for various hemolytic anemia subtypes. Leveraging patient registries, advocacy groups, key opinion leaders (KOLs), and other solutions, our enrollment programs connect you to patients around the world that match your demographics and criteria.
- Once your patients have been recruited, we leverage our expertise in patient engagement and education to ensure retention, participation, and adherence to treatment.
- Additionally, our focus on decentralized trials and patient-centric solutions offers participation options for patients that present severe symptoms, such as from autoimmune hemolytic anemia (AIHA), that prevent them from traveling to clinical sites or leaving their home.
Connect with us to find the right strategy for your next hematology trial. CONTACT US TODAY
